title: Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.
abstract: BACKGROUND
  CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified.
  
  
  OBJECTIVE
  We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis.
  
  
  METHODS
  A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model.
  
  
  RESULTS
  Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P < .01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor.
  
  
  CONCLUSIONS
  The major limitation was the small sample size.
  
  
  CONCLUSIONS
  CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.
authors.affiliation: Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. junoka71@dermatol.med.kyushu-u.ac.jp
authors.forename: Junna
authors.initials: J
authors.lastname: Oba
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nakahara
authors.forename: Sayaka
authors.initials: S
authors.lastname: Hayashida
authors.forename: Makiko
authors.initials: M
authors.lastname: Kido
authors.forename: Lining
authors.initials: L
authors.lastname: Xie
authors.forename: Masakazu
authors.initials: M
authors.lastname: Takahara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uchi
authors.forename: Shogo
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Takeru
authors.initials: T
authors.lastname: Abe
authors.forename: Akihito
authors.initials: A
authors.lastname: Hagihara
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Moroi
authors.forename: Masutaka
authors.initials: M
authors.lastname: Furue
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D015260:Neprilysin / Q000096:biosynthesis*; D011237:Predictive Value of Tests; D011379:Prognosis; D012878:Skin Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
chemical_list: D015260:Neprilysin